Product Program year 2025 Source: CMS Open Payments

Adbry

Biological Dermatology

NDC 50222-346-02

Open in the dashboard

General payments

$10,877,752

153,311 payments

Research payments

$1,194,429

228 payments

Through program year 2025, $10,877,752 in general payments and $1,194,429 in research payments were reported against Adbry (Dermatology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

8 rows
Year Kind Amount Payments
2025 General $2,976,642 37,784
2025 Research $86,041 2
2024 General $2,534,155 37,523
2024 Research $229,905 5
2023 General $2,637,122 36,442
2023 Research $784,726 165
2022 General $2,729,833 41,562
2022 Research $93,757 56

Breakdown

Who paid General payments · program years 2022–2025
  1. LEO Pharma Inc. $10,783,316 153,140 payments
  2. LEO Pharma AS $94,436 171 payments
Top recipients General payments · program year 2025
  1. U Of U Hospitals & Clinics Teaching hospital · UT $398,064 13% · 5 payments
  2. Naiem Issa Dermatology · Vienna, VA $96,510 3% · 92 payments
  3. Firas Hougeir Dermatology · Douglasville, GA $89,484 3% · 36 payments
  4. Mark Marchitto Dermatology · Cromwell, CT $68,829 2% · 80 payments
  5. Matthew Zirwas Dermatology · Bexley, OH $68,202 2% · 54 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Dermatology $1,573,006 64% · 3,539 practitioners
  2. Physician Assistant $355,324 14% · 2,539 practitioners
  3. Physician Assistant, Medical Physician Assistant $133,425 5% · 700 practitioners
  4. MOHS-Micrographic Surgery Dermatology $105,058 4% · 289 practitioners
  5. Nurse Practitioner, Family Nurse Practitioner $75,662 3% · 723 practitioners

The top 5 of 87 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Utah $413,491 14% · 108 recipients
  2. California $322,300 11% · 1,075 recipients
  3. New York $249,634 8% · 805 recipients
  4. Connecticut $171,965 6% · 216 recipients
  5. Virginia $168,758 6% · 242 recipients

The top 5 of 50 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

6,777

Prescriptions dispensed, refills included

Drug cost

$25,549,110

Paid at the pharmacy, in all

Medicare Part D drugs matched to ADBRY, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Adbry Tralokinumab-Ldrm Same name 401 6,691 $25,231,419
Adbry Autoinjector Tralokinumab-Ldrm Similar name 4 86 $317,691

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Melissa Knuckles Dermatology KY 195 $734,806 $25,827
Henry Yu Physician Assistant NY 129 $441,862 $24,270
George Drew Dermatology OH 56 $194,586 $9,460
Austin Hardy Physician Assistant NY 56 $176,315 $12,172
Jerald Hurdle Interventional Pain Management ME 52 $202,946 $204

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
153,311 general · 228 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record